Immunitybio is trading at $9.36, up +10.71%, as retail speculation intensifies around Nant’s planned blockchain and tokenized-stock platform.
- No confirmed Immunitybio announcement dated September 22, 2026, has been identified.
- The broader biotech sector is also rising, supporting risk appetite, while mixed major indexes provide limited additional confirmation.
- The move appears driven by speculative interest alongside sector strength rather than a verified company-specific catalyst.